Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Gains from Investment Securities (2016 - 2025)

Pediatrix Medical (MD) has disclosed Gains from Investment Securities for 16 consecutive years, with -$122000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 112.63% to -$122000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 16.59% increase, with the full-year FY2025 number at $3.5 million, up 16.59% from a year prior.
  • Gains from Investment Securities was -$122000.0 for Q4 2025 at Pediatrix Medical, down from $2.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.5 million in Q4 2023 to a low of -$14.6 million in Q4 2021.
  • A 5-year average of -$247666.7 and a median of $359500.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 6685.56% in 2022, then skyrocketed 1389.1% in 2025.
  • Pediatrix Medical's Gains from Investment Securities stood at -$14.6 million in 2021, then soared by 178.59% to $11.4 million in 2022, then grew by 9.56% to $12.5 million in 2023, then crashed by 92.29% to $966000.0 in 2024, then crashed by 112.63% to -$122000.0 in 2025.
  • Per Business Quant, the three most recent readings for MD's Gains from Investment Securities are -$122000.0 (Q4 2025), $2.1 million (Q3 2025), and $6.1 million (Q2 2025).